When was AlloSource founded?

AlloSource was founded in 1994.

Where is AlloSource located?

AlloSource is headquartered in Centennial, United States. It is registered at Centennial, Colorado.

How many employees does AlloSource have?

As of Jun 30, 2026, the latest employee count at AlloSource is 413.

Is AlloSource a funded company?

AlloSource is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does AlloSource rank among its competitors?

AlloSource ranks 104th amongst 249 active competitors, of which 77 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Pandorum, which secured $429K in Mar, 2026.

Who are the top competitors of AlloSource?

AlloSource's top competitors include Tenaya Therapeutics, Pandorum and Athira Pharma. Among them, Pandorum secured the most recent funding round in March, 2026.

AlloSource - 2026 Company Profile & Competitors

AlloSource is a funded company based in Centennial (United States), founded in 1994. It operates as an AlloSource: Advancing tissue therapies through innovation and allograft solutions. The company has 249 active competitors, including 77 funded and 47 that have exited. Its top competitors include companies like Tenaya Therapeutics, Pandorum and Athira Pharma.

Company Details

AlloSource: Advancing tissue therapies through innovation and allograft solutions. This organization is dedicated to creating enhanced human tissue products, offering a diverse portfolio of allografts. They specialize in tissue types such as acellular dermal matrix, amnion, cartilage, and various bone matrices. Their products cater to specialty areas including burn treatment, foot & ankle, orthopedics, plastics/reconstruction, spine, sports medicine, urogynecology, and wound care. They operate as a mission-driven business, partnering with independent distributors to provide customer support and access to a growing biologics portfolio. They are involved in placenta donation programs and prioritize tissue processing & safety. This company focuses on advancing tissue therapies and improving lives through donation and transplantation.

Website: allosource.org
Social
Registered Address: Centennial, Colorado

Key Metrics

Founded Year

1994

Location

Centennial, United States

Stage

Funding Raised

Ranked

104^th among 249 active competitors

Employee Count

413 as on Jun 30, 2026

Similar Companies

Tenaya Therapeutics & 305 more

View AlloSource's full profile

AlloSource is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Allosource CIN: 841327507 , United States, Active	Dec 26, 999	-	512 (As on Dec 31, 2024)	-

AlloSource is a funded company.

AlloSource's employee count trend

AlloSource has 413 employees as of Jun 26. Here is AlloSource's employee count trend over the years:

Uncover AlloSource's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of AlloSource include Tenaya Therapeutics, Pandorum and Athira Pharma. Here is the list of Top 10 competitors of AlloSource, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Tenaya Therapeutics 2016, San Francisco (United States), Public	Developer of regenerative and gene therapeutics for heart failure	$248M	RTW Investments, Fidelity Investments & 7 others	70/100
2nd	Pandorum 2011, Bengaluru (India), Series B	Developer of regenerative medicine and 3D tissues	$52.1M	Indian Angel Network, BTB Venture & 86 others	65/100
3rd	Athira Pharma 2011, Seattle (United States), Public	Developer of drugs for neurodegenerative diseases	$121M	Dolby Family Ventures, Alzheimer's Drug Discovery ... & 22 others	65/100
4th	Ossio 2014, Caesarea (Israel), Series C	Bone regeneration biocomposite	$89M	MVM, Questa Capital & 7 others	64/100
5th	Tune Therapeutics 2009, Seattle (United States), Series B	Developer of cell and gene therapy by using the epigenomic platform	$222M	New Enterprise Associates, Emerson Collective ... & 8 others	63/100
6th	Orca Bio 2016, Menlo Park (United States), Series F	Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders	$300M	Lightspeed Venture Partners, Mubadala Capital ... & 11 others	63/100
7th	RevBio 2014, Lowell (United States), Series B	Developer of synthetic adhesive used for bone/dental repair	$27.5M	Pacific Dental Services, HHS & 4 others	63/100
8th	LIfT Biosciences 2016, London (United Kingdom), Series A	Developer of neutrophil-based cell therapies for solid tumors	$20.1M	Kizoo, Downing & 13 others	61/100
9th	Stellular Bio 2014, Watertown (United States), Series A	Developer of a platform for producing allogeneic, stem-cell-derived platelet-like cells	$37.5M	Qiming, Vivo Capital & 5 others	61/100
10th	Theradaptive 2004, Boston (United States), Series A	Developer of protein engineering technology creating targeted therapeutics for tissue repair	$50M	TEDCO, Defense.gov & 4 others	61/100
104th	AlloSource 1994, Centennial (United States), Funding Raised	AlloSource: Advancing tissue therapies through innovation and allograft solutions	-	-	44/100